Prostate cancer
Conditions
Interventions
MMR deficiency:None
MMR normal:None
Sponsors
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed prostate adenocarcinoma; 2. Prostate cancer tissue can be obtained for immunohistochemical staining of MLH1, MSH2, MSH6 and PMS2 MMR proteins; 3. Patients who will receive radical surgery, postoperative pathology indicates that lymph nodes are positive, and patients who will receive adjuvant endocrine therapy or are unable to receive surgical treatment for moderate, high-risk localized or locally advanced prostate cancer who will receive radiotherapy combined with endocrine therapy;
Exclusion criteria
Exclusion criteria: 1. Patients with life expectancy less than 1 year; 2. Patients with other tumor diseases; 3. Prostate cancer with other pathological types other than adenocarcinoma; 4. Patients with metastatic prostate cancer confirmed by imaging examination; 5. Patients who have received immunosuppressive therapy or have immune deficiency diseases; 6. Patients with severe liver function damage (Child-Pugh C); 7. Patients with severe renal function injury requiring long-term dialysis treatment; 8. Patients with severe myelosuppression and severe neutropenia; 9. Participate in other clinical studies from 30 days before enrollment to the completion of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Proportion of Patients With PSA Complete Response;Clinial stage;Pathological grade; | — |
Countries
China
Contacts
Public ContactChunguang Yang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed